n update to my column yesterday about Aerie Pharmaceuticals (AERI) and what I called an under-appreciated manufacturing risk related to its glaucoma drug Rhopressa, now under review at the FDA.

It now looks like I over-appreciated the Rhopressa manufacturing challenge.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Get rid of short shill Adam FEURSTEIN Or lose business

    This guy is a known basher of great companies
    He’s a shill for short hedge funds

    Why didn’t you check his background?

    STAT better be smart

    You guys are gonna lose subscribers

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy